Haiko J. Bloemendal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Haiko J. Bloemendal has a total of 174 co-authors. Here are the top co-authors by number of shared publications:
- Cilla E. J. Vrinzen
IQ Health, Radboud University Medical Center, Nijmegen, the Netherlands
14 shared publications - Linn Delfgou
Scientific Institute for Quality of Healthcare, Radboudumc, Nijmegen, The Netherlands
14 shared publications - Matthias Adrianus Wilhelmus Merkx
Department of Oral and Maxillofacial Surgery, Radboud University Medical Centre, Nijmegen, The Netherlands
14 shared publications - Niek Stadhouders
Science department IQ Health, Radboud University Medical Center, Nijmegen, The Netherlands; Department of Health Economics, School of Business and Economics, Talma Institute, Vrije Universiteit, Amsterdam, The Netherlands
14 shared publications - Patrick Paulus Theodoor Jeurissen
Department of IQ Health, Radboud university medical center, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, The Netherlands
14 shared publications - Rosella Petronella Maria Gemma Hermens
Radboud University Medical Center
14 shared publications
Latest Publications
- 19 January 2026
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 96 (1) , 9
Mapping drug-drug interactions in pharmacokinetic boosting of olaparib
Introduction In pharmacokinetic (PK) boosting, an intentional drug-drug interaction (DDI) is used to increase the exposure of another drug. PK boosting of the anticancer drug olaparib with the potent Cytochrome P450 (CYP3A)-inhibitor cobicistat can improve oral bioavailability, tolerability, and affordability. Cancer patients often present with many comedications that can also be affected by CYP3A-inhibitors, which requires thorough assessment of DDIs. This may hamper the feasibility of boosting. Here, we report potential DDIs between cobicistat and comedication in a retrospective cohort of patients treated with olaparib and how these DDIs can be mitigated. Methods Patients who received olaparib between April 2017 and February 2024 were included. Comedications at the start of olaparib treatment were screened for potential DDIs with cobicistat if PK boosting would have been initiated in these patients. Relevant DDIs were reviewed by an expert panel of pharmacists and clinical pharmacologists and recommendations for mitigating interventions were formulated. Results In total, 97 patients were included with a median of six concomitant medications per patient (range 0–13). 59% of patients presented with at least one relevant DDI. With the recommended interventions, 14% of patients had a DDI that required additional monitoring and 1% had a contra-indicated DDI. Conclusions DDIs were highly prevalent when PK boosting of olaparib is applied. Nonetheless, nearly all DDIs could be mitigated by an intervention and most interventions could be applied without additional monitoring. PK boosting of olaparib with cobicistat is thus considered feasible with appropriate expertise and resources.
- 19 January 2026
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 96 (1) , 9
Mapping drug-drug interactions in pharmacokinetic boosting of olaparib
Introduction In pharmacokinetic (PK) boosting, an intentional drug-drug interaction (DDI) is used to increase the exposure of another drug. PK boosting of the anticancer drug olaparib with the potent Cytochrome P450 (CYP3A)-inhibitor cobicistat can improve oral bioavailability, tolerability, and affordability. Cancer patients often present with many comedications that can also be affected by CYP3A-inhibitors, which requires thorough assessment of DDIs. This may hamper the feasibility of boosting. Here, we report potential DDIs between cobicistat and comedication in a retrospective cohort of patients treated with olaparib and how these DDIs can be mitigated. Methods Patients who received olaparib between April 2017 and February 2024 were included. Comedications at the start of olaparib treatment were screened for potential DDIs with cobicistat if PK boosting would have been initiated in these patients. Relevant DDIs were reviewed by an expert panel of pharmacists and clinical pharmacologists and recommendations for mitigating interventions were formulated. Results In total, 97 patients were included with a median of six concomitant medications per patient (range 0–13). 59% of patients presented with at least one relevant DDI. With the recommended interventions, 14% of patients had a DDI that required additional monitoring and 1% had a contra-indicated DDI. Conclusions DDIs were highly prevalent when PK boosting of olaparib is applied. Nonetheless, nearly all DDIs could be mitigated by an intervention and most interventions could be applied without additional monitoring. PK boosting of olaparib with cobicistat is thus considered feasible with appropriate expertise and resources.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from A Systematic Review and Multilevel Regression Analysis Reveals the Comorbidity Prevalence in Cancer
Supplementary tables and figure
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from A Systematic Review and Multilevel Regression Analysis Reveals the Comorbidity Prevalence in Cancer
Supplementary tables and figure
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Methods from A Systematic Review and Multilevel Regression Analysis Reveals the Comorbidity Prevalence in Cancer
Search strings for the literature search and the quality assesment tools
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Methods from A Systematic Review and Multilevel Regression Analysis Reveals the Comorbidity Prevalence in Cancer
Search strings for the literature search and the quality assesment tools
- Open Access
- 16 September 2024
- Published by Elsevier in Annals of Oncology
- Vol. 35 (12) , 1126-1137
Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trial
- 16 September 2024
- Published by Elsevier in Annals of Oncology
- Vol. 35 (12) , 1126-1137
Open AccessIpilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trial
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Maximizing Treatment Opportunities: Assessing Protocol Waivers’ Impact on Safety and Outcome in the Drug Rediscovery Protocol
An overview of all granted waivers in DRUP
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Maximizing Treatment Opportunities: Assessing Protocol Waivers’ Impact on Safety and Outcome in the Drug Rediscovery Protocol
An overview of all granted waivers in DRUP
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Data from Maximizing Treatment Opportunities: Assessing Protocol Waivers’ Impact on Safety and Outcome in the Drug Rediscovery Protocol
Purpose:Although eligibility criteria are essential in trial design, overly restrictive criteria contribute to low accrual and limited generalizability. To enhance trial inclusivity, there has been growing interest in broadening eligibility criteria, especially for patients with advanced or treatment-refractory disease. Yet, the impact on patient safety remains uncertain. In the Drug Rediscovery Protocol (DRUP), protocol exceptions are frequently requested and occasionally granted. Here we describe the impact of these waivers on treatment safety and efficacy.Experimental Design:DRUP is a multicenter, nonrandomized clinical basket trial treating patients with therapy-refractory cancer with molecularly targeted and immunotherapies outside their registered indications (NCT02925234). Here, all granted waivers were revised, analyzed in terms of safety and efficacy outcome, and comparedwithoutcomes of includedpatientswho didnot receive awaiver.Results:Between September 1, 2016, and September 1, 2021, protocol waivers were granted for 82 patients (8%) of 1,019 included patients in DRUP. Most waivers (45%) were granted for general- or drug-related eligibility criteria; other categories were out-of-window testing, treatment, and testing exceptions. Serious adverse event rate was similar between patients who received a waiver (pW) and patients who did not (pNW): 39% vs. 41%, respectively (P = 0.81). The clinical benefit (either objective response or stable disease ≥ 16 weeks) rate of pW was 40% versus 33% in pNW (P = 0.43).Conclusions:Safety and clinical benefit were preserved in patients for whom a waiver was granted. These data support a more personalized approach in assessing eligibility criteria, especially in trials with widely used and approved drugs accruing patients without other treatment options.See related commentary by Waqar and Govindan, p. 3655
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Maximizing Treatment Opportunities: Assessing Protocol Waivers’ Impact on Safety and Outcome in the Drug Rediscovery Protocol
Purpose:Although eligibility criteria are essential in trial design, overly restrictive criteria contribute to low accrual and limited generalizability. To enhance trial inclusivity, there has been growing interest in broadening eligibility criteria, especially for patients with advanced or treatment-refractory disease. Yet, the impact on patient safety remains uncertain. In the Drug Rediscovery Protocol (DRUP), protocol exceptions are frequently requested and occasionally granted. Here we describe the impact of these waivers on treatment safety and efficacy.Experimental Design:DRUP is a multicenter, nonrandomized clinical basket trial treating patients with therapy-refractory cancer with molecularly targeted and immunotherapies outside their registered indications (NCT02925234). Here, all granted waivers were revised, analyzed in terms of safety and efficacy outcome, and comparedwithoutcomes of includedpatientswho didnot receive awaiver.Results:Between September 1, 2016, and September 1, 2021, protocol waivers were granted for 82 patients (8%) of 1,019 included patients in DRUP. Most waivers (45%) were granted for general- or drug-related eligibility criteria; other categories were out-of-window testing, treatment, and testing exceptions. Serious adverse event rate was similar between patients who received a waiver (pW) and patients who did not (pNW): 39% vs. 41%, respectively (P = 0.81). The clinical benefit (either objective response or stable disease ≥ 16 weeks) rate of pW was 40% versus 33% in pNW (P = 0.43).Conclusions:Safety and clinical benefit were preserved in patients for whom a waiver was granted. These data support a more personalized approach in assessing eligibility criteria, especially in trials with widely used and approved drugs accruing patients without other treatment options.See related commentary by Waqar and Govindan, p. 3655
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Maximizing Treatment Opportunities: Assessing Protocol Waivers’ Impact on Safety and Outcome in the Drug Rediscovery Protocol
An overview of all reported serious adverse events in the study subgroup that received a waiver to participate in the trial
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Maximizing Treatment Opportunities: Assessing Protocol Waivers’ Impact on Safety and Outcome in the Drug Rediscovery Protocol
An overview of all reported serious adverse events in the study subgroup that received a waiver to participate in the trial
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Maximizing Treatment Opportunities: Assessing Protocol Waivers’ Impact on Safety and Outcome in the Drug Rediscovery Protocol
Clinical outcome for all included DRUP patients for whom outcome data were available (n = 1006), stratified according to waiver receival, for the different treatment categories
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Maximizing Treatment Opportunities: Assessing Protocol Waivers’ Impact on Safety and Outcome in the Drug Rediscovery Protocol
Clinical outcome for all included DRUP patients for whom outcome data were available (n = 1006), stratified according to waiver receival, for the different treatment categories
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Data from Maximizing Treatment Opportunities: Assessing Protocol Waivers’ Impact on Safety and Outcome in the Drug Rediscovery Protocol
Purpose:Although eligibility criteria are essential in trial design, overly restrictive criteria contribute to low accrual and limited generalizability. To enhance trial inclusivity, there has been growing interest in broadening eligibility criteria, especially for patients with advanced or treatment-refractory disease. Yet, the impact on patient safety remains uncertain. In the Drug Rediscovery Protocol (DRUP), protocol exceptions are frequently requested and occasionally granted. Here we describe the impact of these waivers on treatment safety and efficacy.Experimental Design:DRUP is a multicenter, nonrandomized clinical basket trial treating patients with therapy-refractory cancer with molecularly targeted and immunotherapies outside their registered indications (NCT02925234). Here, all granted waivers were revised, analyzed in terms of safety and efficacy outcome, and comparedwithoutcomes of includedpatientswho didnot receive awaiver.Results:Between September 1, 2016, and September 1, 2021, protocol waivers were granted for 82 patients (8%) of 1,019 included patients in DRUP. Most waivers (45%) were granted for general- or drug-related eligibility criteria; other categories were out-of-window testing, treatment, and testing exceptions. Serious adverse event rate was similar between patients who received a waiver (pW) and patients who did not (pNW): 39% vs. 41%, respectively (P = 0.81). The clinical benefit (either objective response or stable disease ≥ 16 weeks) rate of pW was 40% versus 33% in pNW (P = 0.43).Conclusions:Safety and clinical benefit were preserved in patients for whom a waiver was granted. These data support a more personalized approach in assessing eligibility criteria, especially in trials with widely used and approved drugs accruing patients without other treatment options.See related commentary by Waqar and Govindan, p. 3655
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Maximizing Treatment Opportunities: Assessing Protocol Waivers’ Impact on Safety and Outcome in the Drug Rediscovery Protocol
Purpose:Although eligibility criteria are essential in trial design, overly restrictive criteria contribute to low accrual and limited generalizability. To enhance trial inclusivity, there has been growing interest in broadening eligibility criteria, especially for patients with advanced or treatment-refractory disease. Yet, the impact on patient safety remains uncertain. In the Drug Rediscovery Protocol (DRUP), protocol exceptions are frequently requested and occasionally granted. Here we describe the impact of these waivers on treatment safety and efficacy.Experimental Design:DRUP is a multicenter, nonrandomized clinical basket trial treating patients with therapy-refractory cancer with molecularly targeted and immunotherapies outside their registered indications (NCT02925234). Here, all granted waivers were revised, analyzed in terms of safety and efficacy outcome, and comparedwithoutcomes of includedpatientswho didnot receive awaiver.Results:Between September 1, 2016, and September 1, 2021, protocol waivers were granted for 82 patients (8%) of 1,019 included patients in DRUP. Most waivers (45%) were granted for general- or drug-related eligibility criteria; other categories were out-of-window testing, treatment, and testing exceptions. Serious adverse event rate was similar between patients who received a waiver (pW) and patients who did not (pNW): 39% vs. 41%, respectively (P = 0.81). The clinical benefit (either objective response or stable disease ≥ 16 weeks) rate of pW was 40% versus 33% in pNW (P = 0.43).Conclusions:Safety and clinical benefit were preserved in patients for whom a waiver was granted. These data support a more personalized approach in assessing eligibility criteria, especially in trials with widely used and approved drugs accruing patients without other treatment options.See related commentary by Waqar and Govindan, p. 3655
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Maximizing Treatment Opportunities: Assessing Protocol Waivers’ Impact on Safety and Outcome in the Drug Rediscovery Protocol
An overview of all granted waivers in DRUP
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Maximizing Treatment Opportunities: Assessing Protocol Waivers’ Impact on Safety and Outcome in the Drug Rediscovery Protocol
An overview of all granted waivers in DRUP